However, the difference between the pooled RRs in the diabetes and non-diabetes groups did not reach statistical significance when the IMPROVE-IT trial was excluded (RR, 0.78; 95% CI, 0.65 to 0.93 in the diabetes subgroup vs.
← all excerpts
Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis.
1
—
—